Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSZH | ISIN: US67577C1053 | Ticker-Symbol: 2H51
Tradegate
25.06.25 | 21:57
0,897 Euro
+0,97 % +0,009
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OCUGEN INC Chart 1 Jahr
5-Tage-Chart
OCUGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8900,91025.06.
0,8810,91225.06.

Aktuelle News zur OCUGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiOcugen stock steady as H.C. Wainwright reiterates buy rating41
MoCarisma, Ocugen's OrthoCellix To Merge In All-atock Deal To Advance NeoCart Technology38
MoOcugen, Inc. - 8-K, Current Report6
OCUGEN Aktie jetzt für 0€ handeln
MoOcugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases181Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform...
► Artikel lesen
16.06.Ocugen gets FDA clearance to begin mid-stage study of OCU410ST23
16.06.Ocugen Says FDA Cleared IND Amendment To Initiate Phase 2/3 Study Of OCU410ST In Stargardt Disease20
16.06.FDA clears Ocugen's phase 2/3 trial for Stargardt disease therapy24
16.06.Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease215MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
► Artikel lesen
11.06.Ocugen To Present at BIO International Convention 202552
05.06.Ocugen, Inc. - 8-K, Current Report19
05.06.Ocugen-Aktie steigt nach Lizenzvereinbarung für Gentherapie in Korea86
05.06.Ocugen stock rises on Korean licensing deal for gene therapy6
05.06.Ocugen signs license deal with Korean company for gene therapy9
05.06.Ocugen inks $11 million gene therapy deal for Korean market22
05.06.Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea185Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen...
► Artikel lesen
28.05.Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit54
27.05.Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment33
27.05.Ocugen: FDA Grants Rare Pediatric Disease Designation For OCU410ST20
27.05.FDA grants Ocugen's OCU410ST rare pediatric disease status5
27.05.Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease300MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
► Artikel lesen
Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,2,9